Evista (raloxifene) is now approved to TREAT osteoporosis

Evista (raloxifene) is now approved to TREAT osteoporosis...it used to be approved only for PREVENTION.

Evista is a "selective estrogen." It acts like estrogen to prevent bone loss...but it doesn't stimulate the uterus or breast.

New research shows that Evista decreases vertebral fractures up to 50%...in postmenopausal women who take it for 3 years.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote